CN118765199A - 心肺病症的治疗 - Google Patents

心肺病症的治疗 Download PDF

Info

Publication number
CN118765199A
CN118765199A CN202280092743.9A CN202280092743A CN118765199A CN 118765199 A CN118765199 A CN 118765199A CN 202280092743 A CN202280092743 A CN 202280092743A CN 118765199 A CN118765199 A CN 118765199A
Authority
CN
China
Prior art keywords
ethyl
formula
biphenyl
trifluoromethyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280092743.9A
Other languages
English (en)
Chinese (zh)
Inventor
E·M·贝克尔-佩尔斯特
H·蒂内尔
M·哈恩
D·郎
G·魏曼
J·纳格尔施密茨
L·迪茨
S·萨利赫
D·容
I·特雷维西
T·芒德里
A·里希特
B·奥勒尼克
B·凯尔
B·罗斯勒
P·费
H·施尔默
G·贝克
C·博特
H·费伯
J·艾格
M·帕里
D·沃德
C·维特雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Pharma AG
Original Assignee
Bayer AG
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Pharma AG filed Critical Bayer AG
Publication of CN118765199A publication Critical patent/CN118765199A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280092743.9A 2021-12-29 2022-12-28 心肺病症的治疗 Pending CN118765199A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21218165.5 2021-12-29
EP21218165 2021-12-29
PCT/EP2022/087954 WO2023126437A1 (en) 2021-12-29 2022-12-28 Treatment of cardiopulmonary disorders

Publications (1)

Publication Number Publication Date
CN118765199A true CN118765199A (zh) 2024-10-11

Family

ID=79025014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280092743.9A Pending CN118765199A (zh) 2021-12-29 2022-12-28 心肺病症的治疗

Country Status (11)

Country Link
US (2) US12138256B2 (cg-RX-API-DMAC7.html)
EP (1) EP4456896A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025501309A (cg-RX-API-DMAC7.html)
KR (1) KR20240144178A (cg-RX-API-DMAC7.html)
CN (1) CN118765199A (cg-RX-API-DMAC7.html)
AU (1) AU2022424376A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244895A1 (cg-RX-API-DMAC7.html)
IL (1) IL313920A (cg-RX-API-DMAC7.html)
MX (1) MX2024008170A (cg-RX-API-DMAC7.html)
TW (1) TW202342034A (cg-RX-API-DMAC7.html)
WO (1) WO2023126437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342034A (zh) 2021-12-29 2023-11-01 德商拜耳廠股份有限公司 心肺病症之治療
AU2022429647A1 (en) 2021-12-29 2024-07-04 Bayer Aktiengesellschaft Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound
CN118717697B (zh) * 2024-09-04 2025-03-25 杭州沐源生物医药科技有限公司 一种盐酸贝尼地平片组合物及其制备方法和应用
CN121714543A (zh) * 2024-09-23 2026-03-24 上海欣药智能科技有限公司 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004002L (sv) 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
IL65501A (en) 1981-05-08 1986-04-29 Astra Laekemedel Ab 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
DE3719924A1 (de) 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
JP2785879B2 (ja) 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な2―アミノテトラリン誘導体
FR2659853A1 (fr) 1990-03-22 1991-09-27 Midy Spa Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
EP0738149B1 (en) 1994-01-10 2006-11-29 Teva Pharmaceutical Industries, Ltd. 1-aminoindan derivatives and compositions thereof
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9827467D0 (en) 1998-12-15 1999-02-10 Zeneca Ltd Chemical compounds
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10109861A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
DE10109859A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige Aminodicarbonsäurederivate
DE10109858A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2006522634A (ja) 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
US20050032873A1 (en) 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
CN101146763A (zh) 2005-03-30 2008-03-19 默克公司 胰高血糖素受体拮抗剂化合物、含有这种化合物的组合物以及使用方法
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
US20090048295A1 (en) 2007-08-13 2009-02-19 Joseph Kent Barbay Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof
CN101939053A (zh) 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
JP2011185957A (ja) 2008-07-04 2011-09-22 Sharp Corp 偏光板、表示装置及びその製造方法
US8653099B2 (en) 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2803688A1 (en) 2010-06-25 2011-12-29 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
BR112014002472A2 (pt) 2011-08-12 2017-04-11 Nissan Chemical Ind Ltd "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento"
RU2640416C2 (ru) 2012-04-16 2018-01-09 Тоа Эйо Лтд. Бициклическое соединение
PL2875003T3 (pl) 2012-07-20 2017-05-31 Bayer Pharma Aktiengesellschaft Nowe kwasy 5-aminotetrahydrochinolino-2-karboksylowe i ich zastosowanie
JP6324956B2 (ja) 2012-07-20 2018-05-16 バイエル・ファルマ・アクティエンゲゼルシャフト 置換アミノインダン−およびアミノテトラリンカルボン酸ならびにその使用
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
WO2019081456A1 (en) * 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
KR20230012494A (ko) 2020-05-20 2023-01-26 바이엘 악티엔게젤샤프트 부틸 (5s)-5-({2-[4-(부톡시카르보닐)페닐]에틸}[2-(2-{[3-클로로-4'-(트리플루오로메틸)[비페닐]-4-일]메톡시}페닐)에틸]아미노)-5,6,7,8-테트라히드로퀴놀린-2-카르복실레이트의 제조 방법
TW202342035A (zh) 2021-12-29 2023-11-01 德商拜耳廠股份有限公司 醫藥乾粉吸入配製物
TW202342034A (zh) 2021-12-29 2023-11-01 德商拜耳廠股份有限公司 心肺病症之治療
AU2022429647A1 (en) 2021-12-29 2024-07-04 Bayer Aktiengesellschaft Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound

Also Published As

Publication number Publication date
CA3244895A1 (en) 2023-07-06
MX2024008170A (es) 2024-12-06
WO2023126437A1 (en) 2023-07-06
AU2022424376A1 (en) 2024-07-04
KR20240144178A (ko) 2024-10-02
IL313920A (en) 2024-08-01
EP4456896A1 (en) 2024-11-06
TW202342034A (zh) 2023-11-01
US12138256B2 (en) 2024-11-12
US20240148715A1 (en) 2024-05-09
JP2025501309A (ja) 2025-01-17
US20250090519A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
US12138256B2 (en) Treatment of cardiopulmonary disorders
US20250281480A1 (en) Pharmaceutical dry powder inhalation formulation
US11491155B2 (en) Salt of a pyrimido[6,1-A]isoquinolin-4-one compound
JP2024028720A (ja) エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US20250263381A1 (en) Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound
US20130035340A1 (en) sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS
CN106163517B (zh) 用于治疗囊性纤维化跨膜传导调节因子介导的疾病的药物组合物
US10265314B2 (en) SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
US20150238456A1 (en) Methods and compositions for administration of oxybutynin
JP2022518944A (ja) 肺動脈性肺高血圧症を治療するための投与レジメンおよび方法
AU2013368298B2 (en) Methods and compositions for administration of oxybutynin
CN103732611B (zh) β-肾上腺素能反向激动剂用于戒烟的用途
WO2004087150A1 (ja) 医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination